Home・Lista de Ações・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Fechado

SetorSaúde

25.2 -4.07

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

25.2

Máximo

26.75

Indicadores-chave
By Trading Economics
Rendimento	-29M -11M
Vendas	-24M 105M
EPS	-0.09
Margem de lucro	-10.717
Funcionários	354
EBITDA	-28M -6.3M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+38.37% upside

Dividendos
By Acuity
Próximos Ganhos	27 de out. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	307M 3.2B
Abertura anterior	29.27
Fecho anterior	25.2

Sentimento de Notícias

By Acuity

27%

73%

83 / 340 Ranking em Healthcare

Arcutis Biotherapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

6 de ago. de 2026, 22:16 UTC

Shares of Arcutis Biotherapeutics Inc. are trading higher in after-market hours, amid cautious investor sentiment following recent jobless claims data.

5 de ago. de 2026, 23:02 UTC

News

Social Media

Arcutis Biotherapeutics reports Q2 net product revenues of $129.9 million and raises full-year sales guidance to $525 million to $540 million. Shares rise in after-market trading.

4 de ago. de 2026, 19:46 UTC

Arcutis Biotherapeutics is advancing during Tuesday's session amid a broader market boost from declining crude oil prices, easing inflation concerns.

3 de ago. de 2026, 21:01 UTC

Arcutis Biotherapeutics Inc shares are lower in after-market trading, continuing a decline despite broader market gains and optimism over lower oil prices.

31 de jul. de 2026, 20:03 UTC

Arcutis Biotherapeutics Inc shares are lower today, continuing a decline since Thursday's close amid broader weak performance and no specific news identified.

30 de jul. de 2026, 23:51 UTC

Arcutis Biotherapeutics shares are lower in after-market trading, reflecting a broader decline since Thursday's close amid mixed Asian equity performance and geopolitical concerns.

29 de jul. de 2026, 19:19 UTC

Arcutis Biotherapeutics Inc. shares are lower as market sentiment reflects concerns over the Federal Reserve's upcoming monetary policy announcement amid inflationary pressures.

28 de jul. de 2026, 18:06 UTC

Arcutis Biotherapeutics Inc. shares are higher today, supported by a broader rally in biotechnology stocks, despite no specific company news identified.

27 de jul. de 2026, 16:07 UTC

Social Media

Arcutis Biotherapeutics gained today after an Overweight rating from MS, which highlighted strong sales expectations for ZORYVE and cash flow break-even prospects.

24 de jul. de 2026, 19:16 UTC

Arcutis Biotherapeutics Inc. shares are lower today, reflecting routine performance within a narrow range amid no specific company news identified.

21 de jul. de 2026, 19:46 UTC

Arcutis Biotherapeutics Inc is trading higher, supported by positive market sentiment from strong earnings reports. Shares remain above their 20-day moving average.

20 de jul. de 2026, 20:14 UTC

Arcutis Biotherapeutics Inc shares are lower in after-market trading. No specific company news was identified to explain this movement.

Comparação entre Pares

Variação de preço

Arcutis Biotherapeutics Inc Previsão

Preço-alvo

By TipRanks

38.37% parte superior

Previsão para 12 meses

Média 36.57 USD 38.37%

Máximo 40 USD

Mínimo 34 USD

Com base em 7 analistas de Wall Street que oferecem metas de preço de 12 meses para Arcutis Biotherapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

7 ratings

Comprar

Manter

Vender

Com base em 7 analistas que deram avaliações de ações para Arcutis Biotherapeutics Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

83 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.